CLGN
What one share of CollPlant Biotechnologies holds
Orthopedic, Prosthetic and Surgical Appliances and Supplies
We are a regenerative and aesthetic medicine company focused on medical aesthetics and 3D bioprinting of tissues and organs. Our products are based on our recombinant human collagen (rhCollagen) that is produced in genetically engineered tobacco plants using our proprietary technology.
CollPlant Biotechnologies’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Sales | $0.19 |
|---|---|
| Profit | −$0.94 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.77 |
| Cash and investments | $0.44 |
| Book value | $0.47 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | $0.46 | −$2.24 | $0.30 | −$1.44 | — | $0.72 |
| 2020 | $0.89 | −$0.84 | $0.06 | −$0.71 | — | $0.64 |
| 2021 | $1.31 | $0.02 | $0.12 | $0.09 | — | $4.19 |
| 2022 | $0.03 | −$1.53 | $0.12 | −$1.36 | — | $2.89 |
| 2023 | $0.96 | −$0.62 | $0.08 | −$0.33 | — | $2.47 |
| 2024 | $0.04 | −$1.45 | $0.04 | −$1.27 | — | $1.18 |
| 2025 | $0.19 | −$0.94 | $0.00 | −$0.77 | — | $0.47 |